COVID-19患者纤维蛋白原产生更致密凝块且聚合动力学改变,部分可由唾液酸增加解释
研究从COVID-19患者和未感染受试者中分离纤维蛋白原,制成2 mg/ml均匀浓度凝块,用共聚焦显微镜、扫描电镜、原子力显微镜及内源和外源纤溶试验表征。COVID-19患者纯化纤维蛋白原形成的凝块显著更硬、更致密,聚合和降解动力学不同,唾液酸含量显著更高;去唾液酸化可消除凝块密度差异,但不恢复正常聚合动力学,且影响外源纤溶速率。
要点
- COVID-19患者纯化纤维蛋白原形成的凝块较未感染者显著更硬、更致密。
- COVID-19患者纤维蛋白原唾液酸含量显著更高,去唾液酸化可消除凝块密度差异。
- 去唾液酸化未恢复正常聚合动力学,但影响外源纤溶速率。
核心结论
- COVID-19患者纤维蛋白原的结构差异而不仅是浓度差异,促成了COVID-19相关血栓特征,这些结构差异至少部分由唾液酸化差异介导。
研究设计与样本
- 研究分离COVID-19患者和未感染受试者的纤维蛋白原,制成2 mg/ml均匀浓度凝块。
- 采用共聚焦显微镜、扫描电子显微镜、原子力显微镜及内源和外源纤溶试验进行表征。
- 用神经氨酸酶消化和NANA试验定量唾液酸残基,并对去唾液酸化纤维蛋白原凝块进行类似检测。
主要发现
- COVID-19患者纯化纤维蛋白原形成的凝块较未感染受试者纤维蛋白原凝块显著更硬、更致密。
- 内源和外源纤溶试验显示,COVID-19患者纯化纤维蛋白原的凝块聚合和降解动力学与未感染受试者不同。
- NANA试验显示SARS-CoV-2阳性纤维蛋白原样本的唾液酸残基显著更多。
- 神经氨酸酶去唾液酸化可消除凝块密度差异,但未使聚合差异正常化,且影响外源纤溶速率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombogenicity is a known complication of COVID-19, resulting from SARS-CoV-2 infection, with significant effects on morbidity and mortality. OBJECTIVE: We aimed to better understand the effects of COVID-19 on fibrinogen and the resulting effects on clot structure, formation, and degradation. METHODS: Fibrinogen isolated from COVID-19 patients and uninfected subjects was used to form uniformly concentrated clots (2 mg/ml), which were characterized using confocal microscopy, scanning electron microscopy, atomic force microscopy, and endogenous and exogenous fibrinolysis assays. Neuraminidase digestion and subsequent NANA assay were used to quantify sialic acid residue presence; clots made from the desialylated fibrinogen were then assayed similarly to the original fibrinogen clots. RESULTS: Clots made from purified fibrinogen from COVID-19 patients were shown to be significantly stiffer and denser than clots made using fibrinogen from noninfected subjects. Endogenous and exogenous fibrinolysis assays demonstrated that clot polymerization and degradation dynamics were different for purified fibrinogen from COVID-19 patients compared with fibrinogen from noninfected subjects. Quantification of sialic acid residues via the NANA assay demonstrated that SARS-CoV-2-positive fibrinogen samples contained significantly more sialic acid. Desialylation via neuraminidase digestion resolved differences in clot density. Desialylation did not normalize differences in polymerization, but did affect rate of exogenous fibrinolysis. DISCUSSION: These differences noted in purified SARS-CoV-2-positive clots demonstrate that structural differences in fibrinogen, and not just differences in gross fibrinogen concentration, contribute to clinical differences in thrombotic features associated with COVID-19. These structural differences are at least in part mediated by differential sialylation.
引用
- Moiseiwitsch N, Zwennes N, Szlam F, et al. COVID-19 patient fibrinogen produces dense clots with altered polymerization kinetics, partially explained by increased sialic acid. J Thromb Haemost. 2022. PMID: 36111490. doi:10.1111/jth.15882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。